Effects of sevelamer carbonate on advanced glycation end products and antioxidant/pro-oxidant status in patients with diabetic kidney disease

Clinical Journal of the American Society of Nephrology

Volumn 10, Issue 5, 2015, Pages 759-766

  Yubero Serrano, Elena M ^a,h   Woodward, Mark ^b,c,i   Poretsky, Leonid ^d,e,i   Vlassara, Helen ^d,f,i   Striker, Gary E ^e,f,g,i   Age Less Study Group, ⁱ   Busta, Agustin ⁱ   Harbord, Nikolas B ⁱ   Dadzie, Kobena ⁱ   Islam, Julie ⁱ   Ali, Usman ⁱ   Tamler, Ronald ⁱ   Parikh, Grishma ⁱ   Rayfield, Eliot ⁱ   Rakhlin, Luba ⁱ   Uribarri, Jaime ⁱ   Kent, Rebecca ⁱ   Mantha Thaler, Kamala ⁱ   Polmanteer, Lynn ⁱ   Fendt, Megan ⁱ   Kalaj, Anita ⁱ   McKee, Elizabeth ⁱ   Tripp, Elizabeth ⁱ   Pyzik, Renata A ⁱ   Tirri, Lauren ⁱ   Kruckelmann, Johanna F ⁱ   Swamy, Shobha M ⁱ   Chen, Xue ⁱ   Cai, Weijing ⁱ   Elliot, Sharon J ⁱ   more..

^a INSTITUTO DE SALUD CARLOS III   (Spain)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c UNIVERSITY OF SYDNEY   (Australia)

^d Division of Pediatric Endocrinology   (United States)

^e Nephrology Section   (United States)

^f MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^g MOUNT SINAI HEALTH SYSTEM   (United States)

^h HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

ⁱ NONE

Author keywords

[No Author keywords available]

Indexed keywords

6 N CARBOXYMETHYLLYSINE; 8 ISOPROSTANE; ADIPONECTIN; ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; ALBUMIN; CALCIUM CARBONATE; CREATININE; HEMOGLOBIN A1C; METHYLGLYOXAL; SEVELAMER CARBONATE; SIRTUIN 1; TRANSCRIPTION FACTOR NRF2; TUMOR NECROSIS FACTOR RECEPTOR 1; VASCULAR CELL ADHESION MOLECULE 1; 8-EPI-PROSTAGLANDIN F2ALPHA; ANTIDIABETIC AGENT; CHELATING AGENT; ESTROGEN RECEPTOR ALPHA; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN; LYSINE; MESSENGER RNA; METFORMIN; N(6)-CARBOXYMETHYLLYSINE; NFE2L2 PROTEIN, HUMAN; PROSTAGLANDIN F2 ALPHA; SEVELAMER;

ADULT; ALBUMINURIA; ANTIOXIDANT ACTIVITY; ARTICLE; CONTROLLED STUDY; DIETARY INTAKE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; INTENTION TO TREAT ANALYSIS; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; POLYACRYLAMIDE GEL ELECTROPHORESIS; RANDOMIZED CONTROLLED TRIAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SENSITIVITY ANALYSIS; WESTERN BLOTTING; AGE; AGED; ANALOGS AND DERIVATIVES; BLOOD; CAUCASIAN; CLINICAL TRIAL; COMPLICATION; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; GENETICS; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; SEX DIFFERENCE; SINGLE BLIND PROCEDURE;

ADIPONECTIN; ADVANCED GLYCOSYLATION END PRODUCT-SPECIFIC RECEPTOR; AGE FACTORS; AGED; ALBUMINURIA; CHELATING AGENTS; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DINOPROST; ESTROGEN RECEPTOR ALPHA; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GLYCOSYLATION END PRODUCTS, ADVANCED; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INTENTION TO TREAT ANALYSIS; LYSINE; MALE; METFORMIN; MIDDLE AGED; NF-E2-RELATED FACTOR 2; PYRUVALDEHYDE; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; RNA, MESSENGER; SEVELAMER; SEX FACTORS; SINGLE-BLIND METHOD; SIRTUIN 1;

EID: 84929144674     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.07750814     Document Type: Article

References (36)

1. Afkarian M, Sachs MC, Kestenbaum B, Hirsch IB, Tuttle KR, Himmelfarb J, de Boer IH: Kidney disease and increased mortality risk in type 2 diabetes. J Am Soc Nephrol 24: 302–308, 2013
2. Hallan SI, Matsushita K, Sang Y, Mahmoodi BK, Black C, Ishani A, Kleefstra N, Naimark D, Roderick P, Tonelli M, Wetzels JF, Astor BC, Gansevoort RT, Levin A, Wen CP, Coresh J; Chronic Kidney Disease Prognosis Consortium: Age and association of kidney measures with mortality and end-stage renal disease. JAMA 308: 2349–2360, 2012
3. Gohda T, Niewczas MA, Ficociello LH, Walker WH, Skupien J, Rosetti F, Cullere X, Johnson AC, Crabtree G, Smiles AM, Mayadas TN, Warram JH, Krolewski AS: Circulating TNF receptors 1 and 2 predict stage 3 CKD in type 1 diabetes. J Am Soc Nephrol 23: 516–524, 2012
4. Skupien J, Warram JH, Niewczas MA, Gohda T, Malecki M, Mychaleckyj JC, Galecki AT, Krolewski AS: Synergism between circulating tumor necrosis factor receptor 2 and HbA(1c) in determining renal decline during 5-18 years of follow-up in patients with type 1 diabetes and proteinuria. Diabetes Care 37: 2601–2608, 2014
5. Cai W, Ramdas M, Zhu L, Chen X, Striker GE, Vlassara H: Oral advanced glycation endproducts (AGEs) promote insulin resistance and diabetes by depleting the antioxidant defenses AGE receptor-1 and sirtuin 1. Proc Natl Acad Sci U S A 109: 15888–15893, 2012
6. Bucala R, Makita Z, Vega G, Grundy S, Koschinsky T, Cerami A, Vlassara H: Modification of low density lipoprotein by advanced glycation end products contributes to the dyslipidemia of diabetes and renal insufficiency. Proc Natl Acad Sci U S A 91: 9441–9445, 1994
7. Makita Z, Radoff S, Rayfield EJ, Yang Z, Skolnik E, Delaney V, Friedman EA, Cerami A, Vlassara H: Advanced glycosylation end products in patients with diabetic nephropathy. N Engl J Med 325: 836–842, 1991
8. Cai W, He JC, Zhu L, Chen X, Zheng F, Striker GE, Vlassara H: Oral glycotoxins determine the effects of calorie restriction on oxidant stress, age-related diseases, and lifespan. Am J Pathol 173: 327–336, 2008
9. Koschinsky T, He CJ, Mitsuhashi T, Bucala R, Liu C, Buenting C, Heitmann K, Vlassara H: Orally absorbed reactive glycation products (glycotoxins): An environmental risk factor in diabetic nephropathy. Proc Natl Acad Sci U S A 94: 6474–6479, 1997
10. He C, Sabol J, Mitsuhashi T, Vlassara H: Dietary glycotoxins: Inhibition of reactive products by aminoguanidine facilitates renal clearance and reduces tissue sequestration. Diabetes 48: 1308–1315, 1999
11. Uribarri J, Cai W, Ramdas M, Goodman S, Pyzik R, Chen X, Zhu L, Striker GE, Vlassara H: Restriction of advanced glycation end products improves insulin resistance in human type 2 diabetes: Potential role of AGER1 and SIRT1. Diabetes Care 34: 1610–1616, 2011
12. Vlassara H, Striker GE: AGE restriction in diabetes mellitus: A paradigm shift. Nat Rev Endocrinol 7: 526–539, 2011
13. Ward MS, Fortheringham AK, Cooper ME, Forbes JM: Targeting advanced glycation endproducts and mitochondrial dysfunction in cardiovascular disease. Curr Opin Pharmacol 13: 654–661, 2013
14. Vlassara H, Uribarri J, Cai W, Goodman S, Pyzik R, Post J, Grosjean F, Woodward M, Striker GE: Effects of sevelamer on HbA1c, inflammation, and advanced glycation end products in diabetic kidney disease. Clin JAmSoc Nephrol 7: 934–942, 2012
15. Perkovic V, Heerspink HL, Chalmers J, Woodward M, Jun M, Li Q, MacMahon S, Cooper ME, Hamet P, Marre M, Mogensen CE, Poulter N, Mancia G, Cass A, Patel A, Zoungas S; ADVANCE Collaborative Group: Intensive glucose control improves kidney outcomes in patients with type 2 diabetes. Kidney Int 83: 517–523, 2013
16. Doublier S, Lupia E, Catanuto P, Elliot SJ: Estrogens and progression of diabetic kidney damage. Curr Diabetes Rev 7: 28–34, 2011
17. Tuttle KR, Bakris GL, Bilous RW, Chiang JL, de Boer IH, Goldstein-Fuchs J, Hirsch IB, Kalantar-Zadeh K, Narva AS, Navaneethan SD, Neumiller JJ, Patel UD, Ratner RE, Whaley- Connell AT, Molitch ME: Diabetic kidney disease: A report from an ADA Consensus Conference. Diabetes Care 37: 2864–2883, 2014
18. Goldberg T, Cai W, Peppa M, Dardaine V, Baliga BS, Uribarri J, Vlassara H: Advanced glycoxidation end products in commonly consumed foods. J AmDiet Assoc 104: 1287–1291, 2004
19. Uribarri J, Woodruff S, Goodman S, Cai W, Chen X, Pyzik R, Yong A, Striker GE, Vlassara H: Advanced glycation end products in foods and a practical guide to their reduction in the diet. J Am Diet Assoc 110: 911, e12, 2010
20. Waheed S, Matsushita K, Astor BC, Hoogeveen RC, Ballantyne C, Coresh J: Combined association of creatinine, albuminuria, and cystatin C with all-causemortality and cardiovascular and kidney outcomes. Clin J Am Soc Nephrol 8: 434–442, 2013
21. Inker LA, Schmid CH, Tighiouart H, Eckfeldt JH, Feldman HI, Greene T, Kusek JW, Manzi J, Van Lente F, Zhang YL, Coresh J, Levey AS; CKD-EPI Investigators: Estimating glomerular filtration rate fromserum creatinine and cystatin C.N Engl J Med 367: 20–29, 2012
22. Fan L, Levey AS, Gudnason V, Eiriksdottir G, Andresdottir MB, Gudmundsdottir H, Indridason OS, Palsson R, Mitchell G, Inker LA: Comparing GFR estimating equations using cystatin C and creatinine in elderly individuals [published online December 19, 2014]. J Am Soc Nephrol doi:10.1681/ASN.2014060607
23. Vlassara H, Cai W, Goodman S, Pyzik R, Yong A, Chen X, Zhu L, Neade T, Beeri M, Silverman JM, Ferrucci L, Tansman L, Striker GE, Uribarri J: Protection against loss of innate defenses in adulthood by low advanced glycation end products (AGE) intake: Role of the antiinflammatory AGE receptor-1. J Clin Endocrinol Metab 94: 4483–4491, 2009
24. Bryc K, Durand EY, Macpherson JM, Reich D, Mountain JL: The Genetic Ancestry of African Americans, Latinos, and European Americans across the United States. AmJ Hum Genet 96: 37–53, 2015
25. Block GA, Spiegel DM, Ehrlich J, Mehta R, Lindbergh J, Dreisbach A, Raggi P: Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis. Kidney Int 68: 1815–1824, 2005
26. Raggi P, Vukicevic S, Moyses RM, Wesseling K, Spiegel DM: Ten-year experience with sevelamer and calcium salts as phosphate binders. Clin J AmSoc Nephrol 5[Suppl 1]: S31–S40, 2010
27. Ketteler M, Rix M, Fan S, Pritchard N, Oestergaard O, Chasan- Taber S, Heaton J, Duggal A, Kalra PA: Efficacy and tolerability of sevelamer carbonate in hyperphosphatemic patients who have chronic kidney disease and are not on dialysis. Clin J Am Soc Nephrol 3: 1125–1130, 2008
28. Cai W, Uribarri J, Zhu L, Chen X, Swamy S, Zhao Z, Grosjean F, Simonaro C, Kuchel GA, Schnaider-Beeri M, Woodward M, Striker GE, Vlassara H: Oral glycotoxins are a modifiable cause of dementia and the metabolic syndrome in mice and humans. Proc Natl Acad Sci U S A 111: 4940–4945, 2014
29. Astor BC, Hallan SI, Miller ER III, Yeung E, Coresh J: Glomerular filtration rate, albuminuria, and risk of cardiovascular and allcause mortality in theUS population. AmJ Epidemiol 167: 1226–1234, 2008
30. Gupta J, Mitra N, Kanetsky PA, Devaney J, Wing MR, Reilly M, Shah VO, Balakrishnan VS, Guzman NJ, Girndt M, Periera BG, Feldman HI, Kusek JW, Joffe MM, Raj DS; CRIC Study Investigators: Association between albuminuria, kidney function, and inflammatory biomarker profile in CKD in CRIC. Clin J Am Soc Nephrol 7: 1938–1946, 2012
31. Niewczas MA, Gohda T, Skupien J, Smiles AM, Walker WH, Rosetti F, Cullere X, Eckfeldt JH, Doria A, Mayadas TN, Warram JH, Krolewski AS: Circulating TNF receptors 1 and 2 predict ESRD in type 2 diabetes. J Am Soc Nephrol 23: 507–515, 2012
32. Vlassara H, Striker GE: Advanced glycation endproducts in diabetes and diabetic complications. EndocrinolMetab Clin North Am 42: 697–719, 2013
33. Vlassara H, Cai W, Chen X, Serrano EJ, Shobha MS, Uribarri J, Woodward M, Striker GE:Managing chronic inflammation in the aging diabetic patient with CKD by diet or sevelamer carbonate: Amodern paradigm shift. J Gerontol ABiol SciMed Sci 67: 1410–1416, 2012
34. Zheng F, Zeng YJ, Plati AR, Elliot SJ, Berho M, Potier M, Striker LJ, Striker GE: Combined AGE inhibition and ACEi decreases the progression of established diabetic nephropathy in B6 db/db mice. Kidney Int 70: 507–514, 2006
35. Parsa A, Kao WH, Xie D, Astor BC, Li M, Hsu CY, Feldman HI, Parekh RS, Kusek JW, Greene TH, Fink JC, Anderson AH, Choi MJ, Wright JT Jr, Lash JP, Freedman BI, Ojo A, Winkler CA, Raj DS, Kopp JB, He J, Jensvold NG, Tao K, Lipkowitz MS, Appel LJ; AASK Study Investigators; CRIC Study Investigators: APOL1 risk variants, race, and progression of chronic kidney disease. N Engl J Med 369: 2183–2196, 2013
36. Bhalla V, Zhao B, Azar KM, Wang EJ, Choi S, Wong EC, Fortmann SP, Palaniappan LP: Racial/ethnic differences in the prevalence of proteinuric and nonproteinuric diabetic kidney disease. Diabetes Care 36: 1215–1221, 2013